Worldwide Industry for Cell Therapy Biomanufacturing to 2025 - Key Market Trends and Challenges

News provided by

Feb 23, 2021, 16:00 ET

DUBLIN, Feb. 23, 2021 /PRNewswire/ -- The "Cell Therapy Biomanufacturing: Global Markets" report has been added to ResearchAndMarkets.com's offering.

This research report presents an in-depth analysis of the global cell therapy biomanufacturing market by product type, application and region. The report discusses the key inhibitors to the growth of cell therapy biomanufacturing. The report discusses the role of participants in the supply chain from manufacturers to researchers. The report analyzes key companies operating in the global cell therapy biomanufacturing market. In-depth patent analysis in the report will provide a look at the existing and coming technological trends.

In this report, the cell therapy biomanufacturing market is segmented by product type, application and region. Based on product type, the market is segmented into source of cells (T-cells, Dendritic cells, tumor cells and stem cells), and type of therapy (autologous cell therapies, allogeneic cell therapies). The market by application is categorized into cardiovascular diseases, bone repair, neurological disorders, skeletal muscle repair, cancer and others. The market by region is segmented into North America, Europe, Asia-Pacific and ROW.

Report Includes:

23 tables
An overview of the global markets for cell therapy biomanufacturing
Estimation of the market size and analyses of global market trends with data from 2019, 2020, and projections of compound annual growth rates (CAGRs) through 2025
Assessment of market dynamics such as drivers, restraints, opportunities, and identification of growth inhibiting areas that affect the global market
Detailed description of allogeneic (third party donor cells) and autologous (one's own body cells) forms of cell therapy and analysis of its advantages and limitations
Information on clinical trials of cell therapies; insights into regulatory scenarios and initiatives by government organization
Evaluation of current market trends, market size, market forecast, and technological advancements within the industry
Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies; and a relevant patent analysis
Company profiles of major players of the industry, including Bristol-Myers Squibb Co., Caladrius Biosciences Inc., Lonza Group Ltd., Merck KGaA and Novartis AG

There are numerous indications that can be cured using cell therapies, and the number of therapeutic uses is expected to increase. Some of the indications under investigation for treatments using cell therapy are cerebral disorders such as Parkinson's disease and Alzheimer's disease, and cardiovascular disease. Cardiovascular disease could be treated using cell therapies with the aim of restoring normal heart function. Moreover, many studies are underway to improve the safety and efficacy in the treatment of different malignancies. Cell therapy could also be used to cure metabolic disorders such as diabetes mellitus type 1, where there is lack of insulin production in the patient. Researchers are also trying to restore normal liver and kidney function by introducing modified cells of respective origins.

Cell therapy is also a promising technique for the treatment of orthopedic, oncological, neurological and autoimmune diseases. The increase in the potential of cell therapies in the treatment of diseases associated with lungs using stem cell therapies is expected to be a major driver of the market's growth. Another driver is improved understanding of the role of stem cells in inducing development of functional lung cells, from both embryonic stem cells (ESCs) and induced pluripotent stem (iPS) cells. Stem cell therapies provides further understanding of lung biology and repair after lung injury.

An increase in the incidence of cardiovascular diseases, rise in the demand for chimeric antigen receptor (CAR) T cell therapy, and further development of stem cell therapy approaches are driving the market's growth. However, market restraints include the bottlenecks experienced by manufacturers during commercialization of cell therapies and the high costs associated with cell therapies. The rise in the development of allogeneic cell therapy is expected to drive the market's growth. Allogeneic cell therapy involves chemo radiotherapeutic conditioning therapy that is followed by transplantation of hematopoietic stem cells as well as lymphocytes isolated from allogeneic healthy donors for treatment of various chronic diseases. (Allogeneic means from "one person to another," vs. autologous, which means from "one person back to the same person after processing.")

Hematopoietic stem cell transplantation is used for treatment of a variety of blood cancers and hematologic conditions. This transplantation is the most frequently used cell therapy procedure.

Key Topics Covered:

Chapter 1 Introduction

Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Methodology
Market Estimates
Information Sources
Primary Research
Secondary Research
Geographic Breakdown
Analyst's Credentials
Custom Research
Related Reports

Chapter 2 Summary and Highlights

Introduction

Chapter 3 Market and Technology Background

Introduction to Cell Therapy Biomanufacturing
What is Cell Therapy?
Stem Cell Transplantation
Autologous
Allogeneic
Syngeneic
Stem Cell Biomanufacturing and Classification
Based on Ability to Differentiate
Based on Source
Classification of Cell-Based Therapy Technology
Somatic Cell Technologies
Three-Dimensional Technologies
Cell Immortalization Technologies
Genome Editing Technologies
Cell Plasticity Technologies
Ex vivo Gene Modification of Cells Using Viral Vector Technologies
In vivo Gene Modification of Cells Using Viral Vector Technologies
Stem Cell Applications
Mechanism of Cell Therapy
Delivery Method of Cell-Based Therapy
Manufacturing Cell Therapy Models
Role of Contract Manufacturers
Ongoing Clinical Trials
Clinical Trial Network Focused on Stem Cell Treatments

Chapter 4 Market Trends and Challenges

Challenges
Drivers
Restraints
Opportunity

Chapter 5 Market Breakdown by Product Type

Type of Therapy
Source of Cells
Rise in the Demand for Chimeric Antigen Receptor (CAR) T Cell Therapy

Chapter 6 Market Breakdown by Application

Cardiovascular Disease
Microparticles Cell Imitation
Bone Repair
Neurological Disorders
Spinal Cord Injury
Stroke
Parkinson's Disease
Amyotrophic Lateral Sclerosis
Multiple Sclerosis
Cerebral Palsy
Alzheimer's Disease
Vision Restoration
Vertebral Repair
Batten's Disease
Skeletal Muscle Repair
Intrinsic Healing Mechanisms
Cell Therapy Mechanism
Cancer
Other Diseases

Chapter 7 Market Breakdown by Region

Market Overview
North America
U.S.
Canada
Mexico
Europe
Cardiovascular Diseases in Europe
Contributing Factors for Cardiovascular Diseases (CVD)
Germany
U.K.
France
Asia-Pacific
China
India
Japan
Rest of APAC
Rest of the World
South America
Middle East and Africa

Chapter 8 Regulatory Structure

FDA Approvals
Cell Therapy for CBER Regulations
Federal Regulation codes
Collection of Cells
Code of Regulation
Legislation Governing Use of Stem Cell Treatments
EU Determination of Regulatory Status
Regulatory Scenario in India

Chapter 9 Company Profiles

Bone Therapeutics Sa
Bristol-Myers Squibb Co.
Caladrius Biosciences Inc.
Cell Therapies Pty Ltd.
Cellular Biomedicine Group Inc.
Iovance Biotherapeutics Inc.
Lonza Group Ltd.
Merck Kgaa
Neurogeneration Inc.
Novartis Ag
Regen Biopharma Inc.
Regeneus Ltd.

Chapter 10 Appendix: References

Sources

For more information about this report visit https://www.researchandmarkets.com/r/8pk733

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets